


Lysaker, April 27, 2015 - Exercise of employee share options in PCI Biotech
Holding ASA ("the Company").

1.   Participants in the Company's share option program have on April 27th 2015
exercised a total
number of 174 000 options at a strike price of NOK 4.78.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company's Annual General Meeting May 13th 2014, has decided to
increase the Company's share capital by NOK 522 000 by issuing 174 000 new
shares, of par value NOK 3.00. Subsequent to the transaction the Company's share
capital is NOK 44 701 170 divided into 14 900 390 shares. The capital increase
will result in gross proceeds of NOK 831 720.

2.   Options exercised April 27th 2015

The primary insider and CEO, Per Walday, has exercised 60 000 options in the
Company, corresponding to 60 000 shares at a strike price of NOK 4.78.

Other employees have exercised a total of 114 000 options, corresponding to
114 000 shares at a strike price of NOK 4.78.

3.   Transfer of rights

On April 27th 2015, the primary insider, Per Walday CEO, has transferred 60 000
rights to receive shares resulting from the exercise of options to a third
party. The sales amount will be finally determined on the basis of the price
subsequently obtained by the third party when selling the shares in the market.
Still, primary insiders cannot be held liable for losses incurred by the third
party if the shares are later sold below the strike price. Final compensation
for the transferred rights will be reported to Oslo Axess when known.

Other employees transferred a total of 90 000 out of 114 000 rights to receive
shares resulting from the exercise of options to a third party.

4.   Purchase of shares

On April 27th 2015, the primary insider, Per Walday CEO, has entered into an
agreement to use the whole compensation, net of tax, mentioned in item 3 to
purchase shares. When known, the final number of shares, along with the
compensation, will be reported to Oslo Axess.

The other employees have also entered into agreements to use the whole
compensation, net of tax, mentioned in item 3 to purchase shares.

5.   New Holding

After exercising options, the primary insider, Per Walday CEO, holds a total of
126 000 unexercised options in the Company, corresponding to 80 000 unexercised
options at a strike price of NOK 14.07,16 000 unexercised options at a strike
price of NOK 27.38 and 30 000 unexercised options at a strike price of NOK
27.54. Prior to the abovementioned transactions, Per Walday CEO, holds 22 872
shares in the Company and the final new share holding will be reported to Oslo
Axess when known.

For further information, please contact

Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1915383] 
    